Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice
© 2023. The Author(s)..
INTRODUCTION: Breast cancer in males constitutes approximately 1% of all breast cancer cases globally. Despite extensive treatment experience with abemaciclib in women with metastatic breast cancer (MBC), real-world evidence in male MBC is lacking.
METHODS: This analysis was a part of a broader, retrospective study that analyzed electronic medical records and charts of 448 men and women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) MBC who initiated an abemaciclib-containing regimen from January 2017 through September 2019. Data were collected from the Florida Cancer Specialists & Research Institute and the Electronic Medical Office Logistics Health Oncology Warehouse Language™ databases and summarized descriptively. Real-world best response was described: complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).
RESULTS: Data for six male patients with MBC who were treated with abemaciclib in combination with an aromatase inhibitor (AI) or fulvestrant are presented. Four patients were aged ≥ 75 years, and four patients had ≥ 3 metastatic sites, including visceral involvement. Abemaciclib was initiated in/after third-line (≥ 3L) in four patients, and patients had history of treatment with AI (n = 4), chemotherapy (n = 3), and/or prior cyclin-dependent kinase 4 and 6 inhibitors (n = 2) in the metastatic setting. Abemaciclib + fulvestrant was the most common abemaciclib-containing regimen (n = 4). Best response was documented in four patients: 1 each with CR, PR, SD, and PD.
CONCLUSION: Prevalence of male MBC in this dataset was consistent with expected prevalence in the broader population. Most male patients received an abemaciclib-containing regimen in ≥ 3L, with anti-cancer activity observed despite heavy metastatic burden and prior treatments in a metastatic setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Advances in therapy - 40(2023), 5 vom: 30. Mai, Seite 2515-2523 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ring, Alistair [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.05.2023 Date Revised 22.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12325-023-02471-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355003945 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355003945 | ||
| 003 | DE-627 | ||
| 005 | 20231226063431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-023-02471-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1183.xml |
| 035 | |a (DE-627)NLM355003945 | ||
| 035 | |a (NLM)36995468 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ring, Alistair |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characteristics and Outcomes in Cases of US Male Patients with Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2023 | ||
| 500 | |a Date Revised 22.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a INTRODUCTION: Breast cancer in males constitutes approximately 1% of all breast cancer cases globally. Despite extensive treatment experience with abemaciclib in women with metastatic breast cancer (MBC), real-world evidence in male MBC is lacking | ||
| 520 | |a METHODS: This analysis was a part of a broader, retrospective study that analyzed electronic medical records and charts of 448 men and women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) MBC who initiated an abemaciclib-containing regimen from January 2017 through September 2019. Data were collected from the Florida Cancer Specialists & Research Institute and the Electronic Medical Office Logistics Health Oncology Warehouse Language™ databases and summarized descriptively. Real-world best response was described: complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) | ||
| 520 | |a RESULTS: Data for six male patients with MBC who were treated with abemaciclib in combination with an aromatase inhibitor (AI) or fulvestrant are presented. Four patients were aged ≥ 75 years, and four patients had ≥ 3 metastatic sites, including visceral involvement. Abemaciclib was initiated in/after third-line (≥ 3L) in four patients, and patients had history of treatment with AI (n = 4), chemotherapy (n = 3), and/or prior cyclin-dependent kinase 4 and 6 inhibitors (n = 2) in the metastatic setting. Abemaciclib + fulvestrant was the most common abemaciclib-containing regimen (n = 4). Best response was documented in four patients: 1 each with CR, PR, SD, and PD | ||
| 520 | |a CONCLUSION: Prevalence of male MBC in this dataset was consistent with expected prevalence in the broader population. Most male patients received an abemaciclib-containing regimen in ≥ 3L, with anti-cancer activity observed despite heavy metastatic burden and prior treatments in a metastatic setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Abemaciclib | |
| 650 | 4 | |a Male patients | |
| 650 | 4 | |a Metastatic breast cancer | |
| 650 | 4 | |a Outcome | |
| 650 | 4 | |a Treatment pattern | |
| 650 | 7 | |a abemaciclib |2 NLM | |
| 650 | 7 | |a 60UAB198HK |2 NLM | |
| 650 | 7 | |a Fulvestrant |2 NLM | |
| 650 | 7 | |a 22X328QOC4 |2 NLM | |
| 650 | 7 | |a Aminopyridines |2 NLM | |
| 650 | 7 | |a Aromatase Inhibitors |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Karuturi, Meghan |e verfasserin |4 aut | |
| 700 | 1 | |a Smyth, Emily Nash |e verfasserin |4 aut | |
| 700 | 1 | |a Lokhandwala, Tasneem |e verfasserin |4 aut | |
| 700 | 1 | |a Sheffield, Kristin M |e verfasserin |4 aut | |
| 700 | 1 | |a Willey, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Lunacsek, Orsolya |e verfasserin |4 aut | |
| 700 | 1 | |a Sapunar, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Zhanglin Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Coutinho, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Rybowski, Sarah |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 40(2023), 5 vom: 30. Mai, Seite 2515-2523 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:5 |g day:30 |g month:05 |g pages:2515-2523 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-023-02471-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 5 |b 30 |c 05 |h 2515-2523 | ||